Drug-Drug Interaction Study With BIA 28-6156 and Clarithromycin, Midazolam, and Dabigatran Etexilate in Healthy Participants

2025-520840-14-00 Protocol BIA-28-6156-113 Human pharmacology (Phase I) - Other Ended

Start 29 Apr 2025 · End 24 Jul 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BIA-28-6156-113

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 32
Countries 1
Sites 1

Healthy volunteers

Key facts

Sponsor
Bial Portela & Ca S.A.
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
29 Apr 2025 → 24 Jul 2025
Decision date (initial)
2025-04-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteers

VersionLevelCodeTermSystem organ class
20.0 PT 10061536 Parkinson's disease 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bial Portela & Ca S.A.

Sponsor organisation
Bial Portela & Ca S.A.
Address
A Avenida Da Siderurgia Nacional
City
Sao Mamede Do Coronado
Postcode
4745-457
Country
Portugal

Scientific contact point

Organisation
Bial Portela & Ca S.A.
Contact name
scientific contact

Public contact point

Organisation
Bial Portela & Ca S.A.
Contact name
scientific contact

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 32 1
Rest of world 0

Investigational sites

Belgium

1 site · Ended
SGS Belgium
SGS-Clinical Research CPU, Drie Eikenstraat 655, 2650, Edegem

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2025-04-29 2025-07-24 2025-04-29 2025-07-01

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-03-06 Belgium Acceptable
2025-04-08
2025-04-08
2 SUBSTANTIAL MODIFICATION SM-1 2025-04-17 Belgium Acceptable
2025-05-07
2025-05-08